1. Metabolic Enzyme/Protease
  2. Phosphodiesterase (PDE)

Milrinone (Synonyms: Win 47203)

Cat. No.: HY-14252 Purity: 99.78%
Data Sheet SDS Handling Instructions

Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

For research use only. We do not sell to patients.
Milrinone Chemical Structure

Milrinone Chemical Structure

CAS No. : 78415-72-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
50 mg $50 In-stock
100 mg $79 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Featured Recommendations

Related Screening Libraries:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

In Vitro

Milrinone (1 µM) increases PKA activity in hypoxic myocytes to normoxic levels. Milrinone (50 nM) normalizes TP receptor sensitivity in hypoxic myocytes by restoring PKA-mediated regulatory TP receptor phosphorylation[1]. Milrinone significantly reduces NE-induced vasoconstriction, attenuating both NE sensitivity and maximal tension generation. Inhibition of ATP-sensitive K+ channels or voltage-gated K+ channels do not prevent the milrinone-induced attenuation of NE responses[4].

In Vivo

Milrinone (1 μg/kg/min, i.v.) significantly reduces PAP, PVR (−18.96 ± 1.7%), and LAP (−26.03 ± 2.3%) in congestive heart failure (CHF) rats. Milrinone (1 mg/mL, inhalation) results in a near-maximal reduction of PAP without significant effects on AP, decreases pulmonary artery pressure similarly in a larger collective of CHF rats. Milrinone inhalation selectively increases cAMP but not cGMP plasma concentrations in both groups. Repeated milrinone inhalations even reduce lung wet/dry weight ratio[2]. Milrinone (49.5 μg) largely shifts the ESPVR upwards and significantly increases end-systolic pressure (ESP(0.08)) and the systolic pressure-volume area (PVA(0.08)) at a mid-range LV volume (0.08 mL/g myocardium). Milrinone also slightly decreases LV ESP(ESV) and decreased Ea[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01088997 Children's Hospital of Philadelphia|University of Pennsylvania|Bedford Pharmaceuticals|American Medical Association|Thrasher Research Fund Persistent Fetal Circulation Syndrome June 2010
NCT01725776 Montreal Heart Institute|Canadian Institutes of Health Research (CIHR)|Fonds de la Recherche en Santé du Québec|St. Justine's Hospital Pulmonary Hypertension December 2006 Phase 2
NCT02077010 Vanderbilt University Medical Center|University of Kansas Heart Failure|Cardiomyopathy June 1, 2017 Phase 2
NCT01841177 The Hospital for Sick Children Congenital Heart Disease April 2013 Phase 2
NCT00819377 Andre Denault|Heart and stoke fondation of Quebec|Organon|Canadian Anesthesiologists' Society|Montreal Heart Institute Valvular Stenosis|Valvular Insufficiency|Hypertension, Pulmonary|Coronary Artery Disease February 2009 Phase 2
NCT01621971 Konkuk University Medical Center Pulmonary Hypertension|Mitral Regurgitation January 2003 Phase 3
NCT02951130 NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Congenital Diaphragmatic Hernia|Persistent Pulmonary Hypertension of the Newborn|Hypoxemic Respiratory Failure|Pulmonary Hypoplasia August 1, 2017 Phase 2
NCT01571037 University of Nebraska|Thoratec Corporation End Stage Heart Disease|Right Ventricular Dysfunction April 2012 Phase 1
NCT02595541 Assiut University Pulmonary Hypertension June 2015 Phase 1|Phase 2
NCT01956006 The Alfred Heart Failure October 2013 Phase 1|Phase 2
NCT02098629 Ming-He Huang|Shantou University Medical College|University of Texas Myocardial Reperfusion Injury May 2015 Phase 1|Phase 2
NCT02640846 Sahlgrenska University Hospital, Sweden Septic Shock|Cardiomyopathy December 2015 Phase 4
NCT00543309 John M Costello|American Heart Association|Boston Children’s Hospital Heart Defects, Congenital October 2007 Phase 2
NCT02712788 Indiana University Cerebral Vasospasm April 2016 Phase 2
NCT00966745 Seoul National University Hospital Hepatectomy January 2008
NCT03207165 Ottawa Heart Institute Research Corporation Low Cardiac Output Syndrome|Cardiogenic Shock|Acute Coronary Syndrome|Pulmonary Edema August 2017 Phase 4
NCT02644057 Maimonides Medical Center Cardiorenal Syndrome March 2016 Phase 2
NCT00549107 Ludwig Boltzmann Gesellschaft Low Cardiac Output Syndrome September 2007 Phase 2
NCT02232399 Göteborg University|Helsinki University Central Hospital Congenital Heart Defects October 2014 Phase 2
NCT01849094 The Alfred Healthy|Heart Failure May 2013 Phase 1|Phase 2
NCT00446017 University of Luebeck|Deutsche Stiftung für Herzforschung Cardiac Output, Low June 2003 Phase 3
NCT01576094 Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Hospital Universitario La Paz|Fondo de Investigacion Sanitaria Low Cardiac Output Syndrome November 2009 Phase 1|Phase 2
NCT02408003 Sahlgrenska University Hospital, Sweden Heart Failure, Diastolic|Aortic Valve Stenosis|Monitoring, Physiologic|Physiology March 2014
NCT00338455 Scios, Inc. Congestive Heart Failure|Cardiac Transplantation|Renal Insufficiency|Renal Failure September 2006 Phase 2
NCT02549066 Sahlgrenska University Hospital, Sweden Complication of Extracorporeal Circulation|Kidney Circulation Disorder|Renal Function Disorder January 2016
NCT00695929 Cliniques universitaires Saint-Luc- Université Catholique de Louvain Congenital Cardiovascular Defects|Low Cardiac Output Syndrome July 2008
NCT02726620 Vanderbilt University Medical Center|UMC Utrecht Hypotension January 2017
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 4.7344 mL 23.6720 mL 47.3440 mL
5 mM 0.9469 mL 4.7344 mL 9.4688 mL
10 mM 0.4734 mL 2.3672 mL 4.7344 mL
Animal Administration
[2]

Milrinone is formulated in 0.9% NaCl.

In juvenile rats of 100 ± 8 g body weight (bw), CHF is induced by supracoronary aortic banding. In brief, rats are anesthetized by intraperitoneal injection of ketamine (87 mg/kg bw) and xylazine (13 mg/kg bw). Rats are placed in the supine position, the chest wall is shaved, and a left thoracotomy is performed in the third intercostal space during ventilation with 100% O2. The ascending aorta is freed from connective tissue and partially occluded by implantation of a titanium clip with a defined internal diameter of 0.8 mm. After surgical closure of the thorax, the rats are allowed to recover from anesthesia. For postoperative analgesia, rats receive 250 mg/kg bw of metamizole intramuscularly immediately after the operation and on the first postoperative day. Sham-operated rats serve as controls. After recovery from anesthesia, the animals are placed in cages with free access to water and standard laboratory diet. For inhalation, milrinone (0.2-5 mg/mL) or NaCl (0.9%) are nebulized using an ultrasonic nebulizer and inhaled for 3 min at identical peak inspiratory pressures as used throughout the experiment. A 3-min nebulization of 1 mg/mL milrinone results in vaporization of 14 μg of the phosphodiesterase-3 inhibitor as determined by microgravimetry. Therefore, the respective dose of 39 μg/kg is analog to inhaled doses in human studies. For intravenous delivery, milrinone (initial bolus of 2-10 μg/kg, followed by 0.2-1 μg/kg/min) or equivalent volumes of NaCl (0.9%; initial bolus of 1.6 mL/kg, followed by 10 μL/kg/h) are administered by an infusion pump for 10 min. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

211.22

Formula

C₁₂H₉N₃O

CAS No.

78415-72-2

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 46 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Milrinone
Cat. No.:
HY-14252
Quantity: